ConductScience.org, home

Trial · NCT00619242

The Effects of Sorafenib on Molecular Barrett's Esophagus Cancer

NCT00619242, Not applicable, Terminated, University of Chicago; results first posted 2013-10-21

3 sourcestrials-2026-11-12-0.5.0

Download JSON
Cite this record

ConductScience Library. The Effects of Sorafenib on Molecular Barrett's Esophagus Cancer. Trials, record NCT00619242. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00619242

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title
The Effects of Sorafenib on Molecular Barrett's Esophagus Cancer
NCT number
NCT00619242
Status
Terminated
Phases
Not applicable
Enrollment
3 participants, actual
Lead sponsor
University of Chicago
Conditions
Esophageal Cancer
Interventions
sorafenib
First posted
2008-02-20
Last updated
2014-03-12
Results first posted
2013-10-21

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryKi-67Two weeksBiomarker. Change in Ki-67 staining between pre- and on-therapy biopsies in patients with Barrett's esophagus.

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

TypeOutcomeTime framePopulationUnitsMeasured as
PRIMARYKi-67Two weeksThe 3 subjects underwent therapy without complications however the study was terminated due to low accrual.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow3

How many started, completed or left each group, period by period.

PeriodMilestoneGroupParticipantsUnits counted
Overall StudySTARTEDSorafenib3
Overall StudyCOMPLETEDSorafenib3
Overall StudyNOT COMPLETEDSorafenib0

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals3

The totals the trial posted for each group.

TotalGroupAffectedAt risk
Total, all-cause mortalitySorafenib
Total, other adverse eventsSorafenib03
Total, serious adverse eventsSorafenib03

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov
2026-11-12
ClinicalTrials.gov
Results, from AACT
2026-03-23
AACT
NIH grant links
2026-11-13
NIH RePORTER

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00619242

GET https://conductscience.org/api/trials/v1/NCT00619242/registered